Details for Patent: 10,350,171

« Back to Dashboard

Which drugs does patent 10,350,171 protect, and when does it expire?

Patent 10,350,171 protects CONSENSI and is included in one NDA.

This patent has two patent family members in two countries.

Summary for Patent: 10,350,171

Title:	Celecoxib and amlodipine formulation and method of making the same
Abstract:	Provided herein is a celecoxib and amlodipine composition and method of making the same. The composition contains granules containing celecoxib. The amlodipine is incorporated into the composition as an extragranulate.
Inventor(s):	Yitshak Itsik EFRATI
Assignee:	Dexcel Ltd Israel
Application Number:	US16/008,538
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,350,171
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 10,350,171

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Purple Biotech	CONSENSI	amlodipine besylate; celecoxib	TABLET;ORAL	210045-001	May 31, 2018		DISCN	Yes	No	10,350,171		Y
Purple Biotech	CONSENSI	amlodipine besylate; celecoxib	TABLET;ORAL	210045-002	May 31, 2018		DISCN	Yes	No	10,350,171		Y
Purple Biotech	CONSENSI	amlodipine besylate; celecoxib	TABLET;ORAL	210045-003	May 31, 2018		DISCN	Yes	No	10,350,171		Y

International Family Members for US Patent 10,350,171

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	111065382
World Intellectual Property Organization (WIPO)	2019008583